EDITORIAL BOARD
Steven Vogl, MD
Medical Oncologist
New York City
Steven Vogl, MD
Medical Oncologist
New York City
The ABCSG-18 trial demonstrates that every breast cancer patient being offered adjuvant aromatase inhibitor (AI) therapy should be offered denosumab as well. There are 2 issues involved, either of which would mandate a discussion of using denosumab: One is prevention of fractures not related to cancer, and the other is the prevention of breast cancer relapse.
ABCSG-18 is a large prospective, double-blind, placebo-controlled